Welcome to Bryn Pharma

We are creating A New Way for people to manage their risk of anaphylaxis

Our Mission

Our mission is simple – to offer people with anaphylaxis an affordable, needle-free epinephrine nasal spray that is small enough to comfortably carry in a pocket and easy to use without any special medical training.



Easy to use

Easy to use





Our Commitment

Bryn Pharma was founded by patients who are personally affected by anaphylaxis. The concerns of patients and caregivers like us have informed our approach. Our experience has fueled our drive to find A New Way.

Too many anaphylaxis attacks go untreated — or treatment is delayed — for two key reasons: first, because current emergency epinephrine devices rely on needles, which many people are scared of or aren’t prepared to administer; second, because many people simply don’t carry the appropriate dosage with them (or carry any dosage at all) because the current devices are too big and bulky.1,2

If approved, NDS1C will be a new delivery system for emergency epinephrine use. Epinephrine is the only approved treatment for anaphylaxis. In the early 1900s, epinephrine was developed as a synthetic drug and became widely used in medicine. In the 1960s, doctors started prescribing patients at risk of anaphylaxis a vial of epinephrine and a syringe to manage the condition. In 1987, the FDA approved the first epinephrine autoinjector.3 Since introduction, the autoinjector has become the most popular treatment in outpatient settings.4 Today Bryn is working to continue the path of innovation with the first epinephrine nasal spray.

Meet the Team

We have a unique perspective, we’re patients too

Get to know us

Clinical Development

Bryn Pharma is developing an affordable, needle-free, small, easy to use epinephrine nasal spray to address the needs of patients everywhere

See our progress

Our Product

We're developing an affordable, needle-free, small, easy to use epinephrine nasal spray for patients with anaphylaxis

See our device

Latest News

Learn more about our latest developments

What’s new?

A Patient’s Story

Bryn Pharma’s story started with a mother’s vision

Read Michelle's story

Contact Us

Reach out for information or investment opportunities

Let’s connect
Bryn Pharma

References: 1. Fromer L. Am J Med. 2016;129(12):1244–1250. 2. Bryn Pharma Data on File. 3. Bryn Pharma data on file. 4. Based on 2021 data from Symphony Health, 8.4 million units of Epipen autoinjectors were sold that year vs. 55,000 epinephrine manual syringes.

NDS1C is not currently approved by the FDA or any international regulatory authority.

In accordance with 35 U.S.C. § 287(a), the following list identifies Bryn's rights in U.S. patents associated with the NDS1C. This list may be a subset of Bryn's rights in U.S. patents directed to this product.

U.S. Patent No. 10,688,044
U.S. Patent No. 10,925,841
U.S. Patent No. 11,000,489